THE EFFICACY AND SAFETY OF CO-ADMINISTRATION OF SITAGLIPTIN WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AT HOSPITAL DISCHARGE
THE EFFICACY AND SAFETY OF CO-ADMINISTRATION OF SITAGLIPTIN WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES AT HOSPITAL DISCHARGE
复制标题
DOI：
10.4158/ep-2018-0036
复制
发表时间：
2018-06-01
影响因子：
4.2
通讯作者：
Umpierrez, Guillermo E.
中科院分区：
文献类型：
--
作者：
Gianchandani, Roma Y.;Pasquel, Francisco J.;Umpierrez, Guillermo E.
目的：很少有随机对照试验关注2型糖尿病（T2D）患者从住院到门诊过渡期间的最佳管理。本多中心开放标签研究探讨了基于入院血红蛋白浓度（HbAlc）的出院策略，以指导普通内科和外科T2D患者的治疗。方法：HbA1c为9%（75）的患者出院时使用西格列汀二甲双胍和甘精IT-100，剂量为医院日剂量的50%或80%。主要结局是出院后3个月和6个月HbA lc的变化。结果：整个队列（N = 253）入院时的平均HbA1c为8.70 +/- 2.3%，3个月和6个月时分别降至7.30 +/- 1.5%和7.30 +/- 1.7% （P < 0.05）
Objective: Few randomized controlled trials have focused on the optimal management of patients with type 2 diabetes (T2D) during the transition from the inpatient to outpatient setting. This multicenter open-label study explored a discharge strategy based on admission hemoglobin Ale (HbAlc) to guide therapy in general medicine and surgery patients with T2D.Methods: Patients with HbA1c 9% (75 nunolimol) were discharged on sitagliptinmetformin with glargine IT-100 at 50% or 80% of the hospital daily dose. The primary outcome was change in HbA lc at 3 and 6 months after discharge.Results: Mean HbA1c on admission for the entire cohort (N = 253) was 8.70 +/- 2.3% and decreased to 7.30 +/- 1.5% and 7.30 +/- 1.7% at 3 and 6 months (P